Search

Your search keyword '"Murphy, Maureen E."' showing total 516 results

Search Constraints

Start Over You searched for: Author "Murphy, Maureen E." Remove constraint Author: "Murphy, Maureen E."
516 results on '"Murphy, Maureen E."'

Search Results

52. Suppl. Figure 8 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

53. Data from A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers

54. Suppl. Figure 1 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

55. Suppl. Figure 5 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

56. Data from ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma

57. Supp Materials and Methods from A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors

58. Supplementary Data from A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers

59. Suppl Figure 2 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

60. Suppl. Figure 7 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

61. Figure S1-4, TABLES1, S2 from ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma

62. Suppl. Table 1 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

63. Supplemental Figures from A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors

64. Suppl. Figure 6 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

65. Suppl. Figure 3 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

66. Suppl. Figure 4 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors

72. Common activities and predictive gene signature identified for genetic hypomorphs of TP53

79. A functionally significant SNP in TP53 and breast cancer risk in African-American women

81. HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma

83. Fatty acid transporter 2 reprograms neutrophils in cancer

84. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells

87. Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma

89. Mutant p53 regulates Survivin to foster lung metastasis

92. RETRACTED ARTICLE: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance

93. A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors

95. Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism

96. Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser

98. A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers

99. Author response: Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser

100. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma

Catalog

Books, media, physical & digital resources